Schwarzach Im Pongau

Researchers are conducting the Austrian Hypertrophic Cardiomyopathy (HCM) Registry, a prospective multicenter study enrolling patients from various outpatient clinics across Austria, including both academic and non-academic centers. The study focuses on patients with hypertrophic cardiomyopathy, aiming to collect detailed clinical and genetic data to improve understanding and care standards for this condition. The registry supports innovative research and facilitates both cross-sectional and long-term epidemiological analyses to identify evidence gaps in HCM management. Participants will undergo a structured examination that includes evaluation of HCM symptoms, medical and family history, medication use, and detection of HCM-specific warning signs. Clinical assessments will involve electrocardiograms, echocardiography, laboratory tests, and genetic testing. Data collected will be entered into an electronic case report form to enable multicenter data analysis, overseen by a steering committee with representatives from each site. During the study, researchers will monitor all-cause mortality and cardiovascular events over an average follow-up period of 20 years. The study involves ongoing data collection and standardized clinical assessments to harmonize care for HCM patients in Austria. Data access for research requires approval by the steering committee, ensuring regulated use of the information collected throughout the study duration.

Researchers are evaluating whether a fast discharge approach after invasive treatment for acute myocardial infarction (heart attack) is as safe as the standard care. This study focuses on patients with uncomplicated acute myocardial infarction and compares early discharge at about 24 hours to the usual discharge time of more than 36 hours. The main goal is to see if early discharge leads to similar rates of major adverse cardiovascular events within a year after treatment. The study involves randomly assigning participants to a fast discharge group where patients leave the hospital approximately 24 hours after their invasive procedure, or to standard care with discharge after more than 36 hours. The invasive management includes procedures like PCI to treat the blocked artery causing the heart attack. The trial is multicenter and monitors patients closely during the follow-up period. Participants will be monitored for up to 12 months to track major cardiovascular events such as heart attacks, strokes, or death. Researchers will assess safety by recording these events from the time of randomization until the first occurrence during follow-up. Patients undergo careful evaluation before discharge to ensure stability, and the study includes criteria to identify those suitable for early discharge. This long-term monitoring helps determine if the faster discharge strategy is a safe alternative to standard care.

Researchers are evaluating the effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients, focusing especially on those with severe vitamin D deficiency. Previous studies, including the VITdAL-ICU trial, showed no overall benefit for hospital length of stay but suggested a significant mortality reduction in patients with severe vitamin D deficiency. This phase III multicenter, placebo-controlled, double-blind randomized trial aims to confirm these findings in a larger group of critically ill adults. Participants will be randomly assigned to receive either a high dose of vitamin D3 or a placebo. The vitamin D3 group will receive a loading dose of 540,000 IU dissolved in 37.5 ml of medium chain triglycerides, followed by daily doses of 4000 IU (10 drops) for 90 days. The placebo group will receive an identical regimen without the vitamin D3. The study includes an interim analysis after half of the planned 1200 patients have completed 28 days. During the study, participants will be monitored for 28-day mortality as the primary outcome. The study will collect data on safety and health status over the 90-day treatment period. Researchers will track adherence to the daily dosing and monitor participants throughout their ICU stay and follow-up. This trial could provide important evidence about the use of vitamin D3 in severely deficient critically ill patients.